Free Trial

FitLife Brands (FTLF) Competitors

FitLife Brands logo
$13.09 -0.10 (-0.75%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

FTLF vs. BCAX, ABVX, SEPN, ORGO, SIGA, CGEM, ATYR, KMDA, ATAI, and TRML

Should you be buying FitLife Brands stock or one of its competitors? The main competitors of FitLife Brands include Bicara Therapeutics (BCAX), Abivax (ABVX), Septerna (SEPN), Organogenesis (ORGO), Siga Technologies (SIGA), Cullinan Therapeutics (CGEM), aTyr Pharma (ATYR), Kamada (KMDA), atai Life Sciences (ATAI), and Tourmaline Bio (TRML). These companies are all part of the "pharmaceutical products" industry.

FitLife Brands vs. Its Competitors

FitLife Brands (NASDAQ:FTLF) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

FitLife Brands presently has a consensus price target of $20.50, suggesting a potential upside of 57.45%. Bicara Therapeutics has a consensus price target of $31.86, suggesting a potential upside of 228.10%. Given Bicara Therapeutics' higher probable upside, analysts clearly believe Bicara Therapeutics is more favorable than FitLife Brands.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FitLife Brands
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33
Bicara Therapeutics
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00

2.3% of FitLife Brands shares are held by institutional investors. 61.4% of FitLife Brands shares are held by insiders. Comparatively, 15.5% of Bicara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

FitLife Brands has a net margin of 13.85% compared to Bicara Therapeutics' net margin of 0.00%. FitLife Brands' return on equity of 25.59% beat Bicara Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
FitLife Brands13.85% 25.59% 15.26%
Bicara Therapeutics N/A N/A N/A

In the previous week, FitLife Brands had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 2 mentions for FitLife Brands and 1 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 1.87 beat FitLife Brands' score of 0.93 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
FitLife Brands Positive
Bicara Therapeutics Very Positive

FitLife Brands has higher revenue and earnings than Bicara Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FitLife Brands$64.47M1.90$8.98M$0.8415.50
Bicara TherapeuticsN/AN/A-$68MN/AN/A

Summary

FitLife Brands beats Bicara Therapeutics on 9 of the 12 factors compared between the two stocks.

Get FitLife Brands News Delivered to You Automatically

Sign up to receive the latest news and ratings for FTLF and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTLF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FTLF vs. The Competition

MetricFitLife BrandsMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$122.26M$10.26B$5.52B$9.07B
Dividend YieldN/A2.08%5.25%4.02%
P/E Ratio15.5016.2727.7220.25
Price / Sales1.9029.08367.3678.96
Price / Cash13.2622.8437.4258.29
Price / Book3.313.668.045.49
Net Income$8.98M$235.43M$3.18B$250.18M
7 Day Performance-7.66%1.27%3.72%4.78%
1 Month Performance-6.20%1.79%3.72%7.19%
1 Year Performance-18.83%-14.56%29.92%17.26%

FitLife Brands Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FTLF
FitLife Brands
4.0419 of 5 stars
$13.02
-1.3%
$20.50
+57.5%
-18.1%$122.26M$64.47M15.5020News Coverage
BCAX
Bicara Therapeutics
1.4392 of 5 stars
$9.29
+6.7%
$31.86
+242.9%
N/A$475.01MN/A0.0032
ABVX
Abivax
2.5996 of 5 stars
$7.65
+3.4%
$31.00
+305.2%
-37.1%$469.56MN/A0.0061Positive News
High Trading Volume
SEPN
Septerna
1.1907 of 5 stars
$10.57
+0.6%
$26.75
+153.1%
N/A$468.31M$1.08M0.00N/A
ORGO
Organogenesis
4.2778 of 5 stars
$3.66
-0.3%
$6.00
+63.9%
+53.8%$465.55M$482.04M-21.53950Positive News
SIGA
Siga Technologies
2.3281 of 5 stars
$6.52
+0.9%
N/A-19.1%$461.51M$138.72M9.7340News Coverage
Options Volume
CGEM
Cullinan Therapeutics
1.6504 of 5 stars
$7.53
-3.0%
$30.00
+298.4%
-51.1%$457.95MN/A-2.5930News Coverage
Positive News
Gap Up
ATYR
aTyr Pharma
2.1655 of 5 stars
$5.07
+0.8%
$20.20
+298.4%
N/A$447.69M$230K-6.2653Gap Down
High Trading Volume
KMDA
Kamada
3.9632 of 5 stars
$7.75
+0.5%
$14.67
+89.2%
+35.9%$443.36M$160.95M26.72360
ATAI
atai Life Sciences
2.9988 of 5 stars
$2.19
-0.5%
$8.67
+295.7%
+106.8%$440.74M$310K-2.4180
TRML
Tourmaline Bio
1.5754 of 5 stars
$15.99
-3.3%
$49.33
+208.5%
+26.5%$424.84MN/A-4.9844

Related Companies and Tools


This page (NASDAQ:FTLF) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners